{"id":"lilly-bamlanivimab-etesevimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4650379","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T14:28:10.837007","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination therapy consists of two non-competing monoclonal antibodies directed against distinct epitopes on the SARS-CoV-2 spike receptor-binding domain. By simultaneously targeting different regions of the spike protein, the antibodies work synergistically to neutralize viral particles and reduce viral load in infected individuals. The dual-antibody approach was designed to reduce the risk of viral escape and resistance.","oneSentence":"Bamlanivimab and etesevimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:15.397Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (mild to moderate disease in high-risk patients)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT04790786","phase":"PHASE4","title":"UPMC OPTIMISE-C19 Trial, a COVID-19 Study","status":"TERMINATED","sponsor":"Erin McCreary","startDate":"2021-03-10","conditions":"Covid19","enrollment":4571},{"nctId":"NCT04497987","phase":"PHASE3","title":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-02","conditions":"COVID-19, SARS-CoV2","enrollment":1180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lilly Bamlanivimab + Etesevimab","genericName":"Lilly Bamlanivimab + Etesevimab","companyName":"Erin McCreary","companyId":"erin-mccreary","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bamlanivimab and etesevimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection. Used for COVID-19 (mild to moderate disease in high-risk patients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}